All In Biotech

Drug Trial Radar · NCT02576431

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

215

Actual

Start

Sep 30, 2015

Primary completion

Sep 29, 2025

Study completion Sep 29, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.

Conditions

  • Solid Tumors Harboring NTRK Fusion

Interventions

  • BAY2757556 (Larotrectinib, Vitrakvi)Drug

    Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best overall response of confirmed complete response (CR) or partial response (PR) as determined by an independent radiology review committee using RECIST v1.1 or RANO criteria, as appropriate to tumor type.Time frame: Up to 120 months

Locations

98 sites in 25 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Center Palo Alto

    Palo Alto, California

  • UCLA Health Santa Monica Cancer Care

    Santa Monica, California

  • Memorial Cancer Institute at West

    Pembroke Pines, Florida

  • The University of Chicago Medical Center - Hyde Park - Hematology & Oncology

    Chicago, Illinois

  • Mass General Cancer Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute - Oncology Department

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center New York - Main Campus

    New York, New York

  • UNC Hospitals - UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Cleveland Clinic - Neurology

    Cleveland, Ohio

  • Sidney Kimmel Cancer Center - Jefferson Health

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Avera Cancer Institute - Sioux Falls

    Sioux Falls, South Dakota

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center

    Houston, Texas

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • Fred Hutch Cancer Center - Sloan Clinic 1

    Seattle, Washington

  • West Virginia University

    Morgantown, West Virginia

  • Hospital Alemán

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno"

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Fundación Cenit para la Investigación en Neurociencias

    CABA, Ciudad Auton. de Buenos Aires, Argentina

  • Centro Medico Austral

    TBC, Ciudad Auton. de Buenos Aires, Argentina

  • Centro Médico San Roque

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Macquarie University Hospital

    Sydney, New South Wales, Australia

  • Royal Darwin Hospital

    Tiwi, Northern Territory, Australia

  • St John of God Healthcare

    Subiaco, Western Australia, Australia

  • Institut Jules Bordet/Jules Bordet Instituut

    Brussels, Belgium

  • Hosp. Araujo Jorge da Associação de Combate ao Câncer

    Goiânia, Goiás, Brazil

  • Cenantron Centro Avançado de Tratamento Oncológico, Ltda.

    Belo Horizonte, Minas Gerais, Brazil

  • Instituto Nacional do Câncer - INCA - HC II

    Rio de Janeiro, Rio de Janeiro, Brazil

  • INCA - Hospital do Cancer III

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Oncoclínicas Rio de Janeiro S.A

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Fundacao Pio XII - Hospital de Cancer de Barretos

    Barretos/SP, São Paulo, Brazil

  • Instituto do Cancer do Estado de Sao Paulo

    São Paulo, São Paulo, Brazil

  • Real e Benemérita Associação Portuguesa de Beneficência

    São Paulo, São Paulo, Brazil

  • Hospital Sirio Libanes

    São Paulo, São Paulo, Brazil

  • IBCC - Instituto Brasileiro de Controle do Cancer

    São Paulo, São Paulo, Brazil

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Zhongshan Hospital, Fudan University - Oncology Department

    Shanghai, China

  • Beijing Cancer Hospital - Oncology Department

    Beijing, Beijing Municipality, China

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.